Dr Mark Wass
Mark obtained a BA in Natural Sciences from Cambridge University in 2000 followed by an MSc in Computing at Imperial College London (2001). After a few years working in Industry as an IT consultant Mark studied for a PhD with Prof Mike Sternberg at Imperial (2004-2008) and continued onto a post-doctoral position in the group until 2011. In 2011 Mark was awarded a FEBS Long Term Fellowship to work in the group of Alfonso Valencia at the CNIO (Spanish National Cancer Research Centre, Madrid, Spain). Mark joined the School of Biosciences at Kent in October 2012 as a lecturer in Computational Biology and now runs a joint wet/ dry laboratory research group together with Martin Michaelis
Google Scholar: http://tinyurl.com/lsesv4h
Mark’s research focusses in two main areas. The first is the development of novel computational methods for the analysis of large scale biological data, particularly methods for the prediction of protein structure, function and interactions. The second area is the application of such methods to address important biological problems. These cover the association of genetic variation with human disease, investigating mechanisms and biomarkers of acquired resistance to anti-cancer drugs and also identifying determinants of pathogenicity in viruses.
In the area of acquired resistance in cancer, Mark’s research focusses on using the Resistant Cancer Cell Line Collection (RCCL), a unique collection of >1,300 cancer cell lines with acquired resistance to anti-cancer drugs, which provides a model to study how tumours become resistant to anti-cancer drugs during treatment. In the area of computational virology Mark’s research initially focussed on investigating determinants of Ebola virus pathogenicity, in 2016, Mark won the International Society of Computational Biology ‘Fight against Ebola award’. Mark’s continues research on Ebola virus and has expanded this area of research to other other viruses including Marburg virus and Zika virus.
- BI638 – Bioinformatics and Genomics
- BI639 – Frontiers in Oncology
- BI620 – Frontiers in Virology
- BI629 – Proteins
MSc-R projects available for 2019/20
Predicting protein function Advances in sequencing technologies have identified millions of protein sequences but the function of many of these proteins remains unknown. This project will focus on developing a computational method to predict protein function. Additional research costs: £1200
Predicting the effects of genetic variation Millions of genetic variants have been identified within human genomes but it is difficult to identify those that are associated with a phenotype (i.e. disease). This project will develop a computational machine learning approach to predict the effect of genetic variants. Additional research costs: £1200
Investigating determinants of virus pathogenicity (joint supervision with Prof Martin Michaelis)
Our research has recently compared different species of Ebolaviruses to identify parts of their proteins that determine if they are pathogenic. This project will apply these computational approaches to different types of viruses (e.g. Zika virus, west Nile, human papillomavirus) to identify determinants of virus pathogenicity and gain insight into what make some viruses highly virulent while others are harmless. Additional research costs: £1200
Investigation of drug-adapted cancer cell lines (joint supervision with Prof Martin Michaelis) We host the Resistant Cancer Cell Line (RCCL) collection, the worldwide largest collection of drug-adapted cancer cell lines and models of acquired drug resistance in cancer at Kent. In this project, drug-adapted cancer cell lines will be characterised and investigated to gain novel insights into the processes underlying resistance formation and to identify novel therapy candidates (including biomarkers) Additional research costs: £1200
Evolution of the muscle sarcomere. A bioinformatics approach to the interaction between myosin and myosin binding protein-C (joint supervision with Prof M Geeves)
Additional research costs: £1200
Using cancer genomics to identify biomarkers of cancer resistance
(joint supervision with Prof Martin Michaelis)
At Kent we host the Resistant Cancer Cell Line (RCCL) collection, the largest collection of cancer cell lines worldwide that have been adapted to anti-cancer drugs. These cells represent a model of drug resistance in tumours. This project will analyse exome sequencing data of a set of cell lines to identify mechanisms of resistance and biomarkers.
Additional research costs: £1200
Design of cancer cell-specific drug carrier systems (joint supervision Dr Christopher Serpell, School of Physical Sciences)
The Serpell lab has produced perfectly sequence-defined polymers which self-assemble to give nanostructures with a remarkable variety of size and shape according to sequence and conditions (N. Appukutti, C. J. Serpell, Sequence Isomerism in Uniform Polyphosphoesters Programmes Self-Assembly and Folding, ChemRxiv, preprint posted 04.02.19, DOI: https://doi.org/10.26434/chemrxiv.7666316.v1. In this project, the effects of the polymer nanostructure on cell uptake and therapeutic efficacy will be studied in different cancer cells. This will provide pioneering insights into the prospects of sequence-defined polymers as carrier systems for anti-cancer drugs. Additional research costs: £1200